

FO051

**THE IMPACT OF GFR EVALUATION TECHNIQUE ON LIVING
KIDNEY DONATION ELIGIBILITY**

François Gaillard^{1,1}, Marie Courbebaisse², Nassim Kamar⁹, Lionel Rostaing⁷,
Sophie Girerd⁸, Martin Flamant¹, Emmanuelle Vidal-Petiot¹, Lionel Couzi⁵, Paolo
Malvezzi⁷, Marie-Noelle Peraldi⁴, Bruno Moulin¹⁴, Philippe Gatault¹⁰, Nicolas
Maillard¹², Laurence Dubourg¹³, Cyril Garrouste⁶, Christophe Legendre³, Pierre
Delanaye¹⁵, Christophe Mariat¹²

¹Physiology, AP-HP, Bichat Hospital and Paris Diderot University, Sorbonne Paris Cité,
Paris, France, ²Physiology, AP-HP, Georges Pompidou European Hospital and INSERM,

Unit 1151, Paris, France, ³Nephrology and Renal Transplantation, AP-HP, Necker Hospital, Paris, France, ⁴Nephrology, AP-HP, Saint Louis Hospital and Paris Diderot University, Paris, France, ⁵Nephrology, Transplantation, Dialysis and Apheresis, Bordeaux University Hospital and Immuno ConcEPT, CNRS UMR 5164, Bordeaux University, Bordeaux, France, ⁶Nephrology, CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁷Nephrology and Renal Transplantation, CHU Grenoble, Grenoble, France, ⁸Nephrology, CHU Nancy, Nancy, France, ⁹Nephrology and Organ Transplantation, CHU Rangueil and INSERM U1043, IFR¹¹BMT, Université Paul Sabatier, Toulouse, France, ¹⁰Nephrology, Dialysis and Renal Transplantation, CHU Tours and François Rabelais University, EA4245 Cellules Dendritiques, Immunomodulation et Greffes, Tours, France, ¹¹Renal Transplantation, Hôpital Necker, Paris, France, ¹²Nephrology, Dialysis and Renal Transplantation, Hôpital Nord, CHU de Saint-Etienne, Jean Monnet University, COMUE Université de Lyon, Saint-Etienne, France, ¹³Exploration Fonctionnelle Rénale et Métabolique, Hospices Civils de Lyon and 16. UMR 5305 CNRS/Université Claude-Bernard, Biologie Tissulaire et Ingénierie Thérapeutique, Lyon, France, ¹⁴Nephrology and Transplantation, Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg, Strasbourg, France and ¹⁵Nephrology, Dialysis and Renal Transplantation, University of Liège (CHU ULg), Liège, Belgium

INTRODUCTION AND AIMS: Living kidney donation requires evaluation of renal function. Recent KDIGO guidelines for living kidney donors suggest using the “best locally available” technique to evaluate GFR. That could result in using estimated GFR for some donors and measured GFR for others. However, there is a significant discrepancy between those techniques that could impact the decision to donate.

METHODS: To evaluate the impact of GFR evaluation method on eligibility to donation we compared measured GFR with exogenous tracer to estimated GFR with 4 equations (CKD-EPI, MDRD, Full Age Spectrum, and Lund-Malmö). We conducted a multicentric study on 1743 French living kidney donors with enzymatic creatinine dosage and measured GFR.

RESULTS: The CKD-EPI equation has the best overall performance (highest percentage of values within 10% or 30% of measured GFR, 48.8% and 94.4% respectively, lowest rmse, 16.2mL/min/1.73m²). However, decision to donate is frequently based on a GFR threshold: 256 donors had an eGFR_{CKD-EPI} higher than 90mL/min/1.73m² but an mGFR lower. Similarly 103 donors had an eGFR_{CKD-EPI} higher than 80mL/min/1.73m² but an mGFR lower. The CKDEPI equation misclassified 14.7% and 6% of donors respectively. Alternatively, if decision to donate is based on an age-dependent threshold, we evaluated the ability of the CKDEPI equation to detect donors with an mGFR below the 2.5th percentile of mGFR for age. Only 2% of the donors with an mGFR below the 2.5th percentile of mGFR for age also had an eGFR_{CKD-EPI} below the 2.5th percentile for age.

CONCLUSIONS: Even with the best overall performance of the CKDEPI equation, GFR estimation is not adapted to living kidney donors screening. Regardless on the acceptance criteria (fixed or age-dependent GFR threshold) measured GFR and estimated GFR give significantly different information that could change the decision to donate.